-
Mashup Score: 2Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | NEJM - 4 hour(s) ago
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | NEJM - 4 hour(s) ago
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Lovely to see this in print - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | New England Journal of Medicine https://t.co/xmRSpEYpN3
-
-
Mashup Score: 2Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | NEJM - 6 hour(s) ago
Whether fixed-duration acalabrutinib–venetoclax (with or without obinutuzumab) would result in better progression-free survival than chemoimmunotherapy in patients with untreated chronic lymphocyti…
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Lovely to see this in print - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | New England Journal of Medicine https://t.co/xmRSpEYpN3
-
-
Mashup Score: 5
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life Hematology Disease Topics & Pathways: Lymphomas, Diseases, Lymphoid Malignancies Meghan C. Thompson, MD 1, Ricardo D. Parrondo, MD 2, Anna Maria Frustaci, MD 3 *, John N. Allan, MD 4, Paolo Ghia, MD, PhD 5,6, Irina Mocanu, MD 7 *, Constantine S. Tam, MD, MBBS 8, Judith Trotman, FRACP 9, Inhye E. Ahn, MD 10, Stephan Stilgenbauer,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Pretty excited to see back-to-back BTK degrader presentations, BGB-16673 will be presented by @MCThompsonMD - impressive ORR 78% in CLL #cllsm https://t.co/5PBhDFWJc9
-
-
Mashup Score: 8
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphoid Leukemias, CLL, Clinical Research, Diseases, Lymphoid Malignancies Jennifer R. Brown, MD, PhD 1, John F. Seymour, MBBS, PhD 2, Wojciech Jurczak, MD, PhD 3, Andrew Aw, MD 4 *, Malgorzata Wach, MD 5 *, Arpad Illes, MD 6 *, Alessandra Tedeschi, MD 7 *, Carolyn Owen, MD 8, Alan P
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Took an election doom-scrolling break to look at my most anticipated ASH abstract - AMPLIFY trial! AV and AVO with impressive 36 mo PFS (>CIT) - looks like more deaths in AVO arm - ?COVID effect - excited for presentation! #cllsm https://t.co/E1NJxNHX2V
-
-
Mashup Score: 0
Program: Oral and Poster Abstracts Type: Oral Session: 623. Mantle Cell, Follicular, Waldenstrom’s, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Clinical Trials for Marginal Zone Lymphoma, Waldenstrom’s Macroglobulinemia and Hairy Cell Leukemia Hematology Disease Topics & Pathways: Research, Lymphomas, Diseases, Lymphoid Malignancies 1 Department of Clinical Haematology, Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 2 Alfred Hospital and Monash
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
BGB-16673 also looking quite effective in WM - sad I won’t see this oral presentation live as it overlaps with the CLL session 🫠 https://t.co/x4ysbz0XOF
-
-
Mashup Score: 1
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life Hematology Disease Topics & Pathways: Research, Clinical trials, Clinical Research, Treatment Considerations, Biological therapies Nirav N. Shah, MD 1,2, Zulfa Omer, MD 3, Graham P. Collins 4, Francesco Forconi 5 *, Alexey Danilov, MD, PhD 6, John C. Byrd, MD 7, Dima El-Sharkawi 8 *, Emma Searle, MD, PhD 9,10 *, Alvaro J
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Other degrader of interest, NX-5948, also looking promising with ORR 77% in CLL-tx pts #cllsm https://t.co/39dnJoNL9G
-
-
Mashup Score: 4
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life Hematology Disease Topics & Pathways: Lymphomas, Diseases, Lymphoid Malignancies Meghan C. Thompson, MD 1, Ricardo D. Parrondo, MD 2, Anna Maria Frustaci, MD 3 *, John N. Allan, MD 4, Paolo Ghia, MD, PhD 5,6, Irina Mocanu, MD 7 *, Constantine S. Tam, MD, MBBS 8, Judith Trotman, FRACP 9, Inhye E. Ahn, MD 10, Stephan Stilgenbauer,
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Pretty excited to see back-to-back BTK degrader presentations, BGB-16673 will be presented by @MCThompsonMD - impressive ORR 78% in CLL #cllsm https://t.co/5PBhDFWJc9
-
-
Mashup Score: 8
Program: Oral and Poster Abstracts Type: Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Frontline Targeted Therapy Combinations Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphoid Leukemias, CLL, Clinical Research, Diseases, Lymphoid Malignancies Jennifer R. Brown, MD, PhD 1, John F. Seymour, MBBS, PhD 2, Wojciech Jurczak, MD, PhD 3, Andrew Aw, MD 4 *, Malgorzata Wach, MD 5 *, Arpad Illes, MD 6 *, Alessandra Tedeschi, MD 7 *, Carolyn Owen, MD 8, Alan P
Source: ash.confex.comCategories: General Medicine News, Hem/OncsTweet-
Took an election doom-scrolling break to look at my most anticipated ASH abstract - AMPLIFY trial! AV and AVO with impressive 36 mo PFS (>CIT) - looks like more deaths in AVO arm - ?COVID effect - excited for presentation! #cllsm https://t.co/E1NJxNHX2V
-
-
Mashup Score: 12Patient with Newly Diagnosed CLL with High-Risk Features - 3 month(s) ago
A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.
Source: www.onclive.comCategories: General Medicine News, Hem/OncsTweet-
Here’s a fun case based program I did with my good friends Dr Bita Fakhri and Dr John Allan - check it out 😀 @OncLive https://t.co/xtC4otNH4D
-
Lovely to see this in print - Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia | New England Journal of Medicine https://t.co/xmRSpEYpN3